Opdivo Approved for First-Line Treatment of Advanced or Metastatic GI Cancers

The FDA approved nivolumab (Opdivo, Bristol Myers Squibb), in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the initial treatment of patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer and esophageal adenocarcinoma.